Radiofrequency ablation of bone tumors (osteoid-osteoma and osseous metastases)

Warmuth M, Nachtnebel A.

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
Radiofrequency ablation (RFA) is a relatively new, minimally-invasive ablation method that destroys tumors by local application of heat. This systematic review evaluates two indications of RFA for the treatment of bone tumors: osteoid-osteoma (benign bone tumor) and osseous metastases of various primary cancers, such as lung cancer, breast cancer or prostate cancer.

Authors' conclusions
According to GRADE, the quality of evidence is very low due to the uncontrolled study design of the included case-series. Overall, the available evidence is insufficient to assess the efficacy and safety of RFA compared to the respective standard therapy for the treatment of bone tumors. Currently, the inclusion into the hospital benefit catalogue is not recommended.

Final publication URL
http://eprints.hta.lbg.ac.at/958/1/DSD_54.pdf

Indexing Status
Subject indexing assigned by CRD

MeSH
Catheter Ablations; Bone Neoplasms

Language Published
German

Country of organisation
Austria

English summary
An English language summary is available.

Address for correspondence
Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99 Email: marisa.warmuth@hta.lbg.ac.at

AccessionNumber
32012000772

Date abstract record published